Robert B Livingston
Affiliation: University of Arizona
- Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patientsBrenda F Kurland
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
EJNMMI Res 2:34. 2012..abstract:..
- SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancerRobert B Livingston
Arizona Cancer Center, Hematology Oncology Section, Tucson, AZ, 85724 5024, USA
Breast Cancer Res Treat 130:123-31. 2011..The combination of trastuzumab, docetaxel, and vinorelbine is effective as first-line chemotherapy in HER2-positive MBC with minimal toxicity. One-year survival estimates are among the highest reported in this population...
- Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500Jeffrey B Smerage
Jeffrey B Smerage, Anne F Schott, and Daniel F Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing Sheela Tejwani, Henry Ford Hospital, Detroit, MI William E Barlow and Danika L Lew, SWOG Statistical Center Julie R Gralow, Seattle Cancer Care Alliance, Seattle, WA Gabriel N Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX Eric P Winer, Dana Farber Cancer Institute, Boston, MA Brian Leyland Jones, Avera Cancer Institute, Sioux Falls, SD Mark A O Rourke, Greenville Health System Cancer Institute Greenville Community Clinical Oncology Program, Greenville, SC Gerald V Doyle, Immunicon, Huntingdon Valley, PA and Robert B Livingston, University of Arizona Cancer Center, Tucson, AZ
J Clin Oncol 32:3483-9. 2014..A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-line chemotherapy would improve the primary outcome of overall survival (OS)...
- Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancerLeona Downey
Arizona Cancer Center, Tucson, Arizona 85724, USA
Clin Cancer Res 16:1281-8. 2010..This hypothesis was examined using the data from a phase III trial that randomized patients with HER2-negative or HER2-untested metastatic breast cancer to first-line therapy with paclitaxel along with either lapatinib or placebo...